The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This study enrolled 30 healthy volunteers and 30 patients with atopic asthma, for a total of
60 subjects. The study examined the tolerability of omalizumab and omalizumab excipients in
two successive cohorts of subjects, healthy volunteers and patients with allergic asthma
without prior exposure to omalizumab, according to a skin test protocol, consisting of a
prick skin test and/or intradermal test.